GSA Journals
Browse
IMAGE
Figure S3.jpg (242.19 kB)
IMAGE
Figure S2.jpg (1.07 MB)
IMAGE
Figure S1.jpg (878.05 kB)
DOCUMENT
Supporting Information Legends copy.docx (16.54 kB)
1/0
4 files

Supplemental Material for Kushnir et al., 2020

Version 2 2019-12-05, 17:12
Version 1 2019-11-18, 18:11
dataset
posted on 2019-12-05, 17:12 authored by Shaked Bar-Cohen, Navit Mooshayef, Rotem Lange, Allan Bar-Sinai, Helit Rozen, Adi Salzberg, David Engelberg, Ze’ev Paroush

Excessive RTK signaling, often caused by activating mutations in Ras, Raf and/or MEK, occurs in most human tumors. Intriguingly, confirmed cancer-driver mutations in the downstream effector kinase, ERK, have not been reported. To test if active ERK mutants can function as oncoproteins, we introduced an activating mutation, originally identified in a yeast ERK, into the single Drosophila ERK. We find that this mutation renders ERK catalytically active independently of upstream signaling, and that its expression induces extensive over-proliferation and hyperplastic tumor formation in vivo. Thus, some human ERK1/2 mutations identified in patient-derived tumours may actually represent overlooked oncogenic, cancer-causing mutations.


History

Article title

An Activating Mutation in ERK Causes Hyperplastic Tumors in a scribble Mutant Tissue in Drosophila

Manuscript #

GENETICS/2019/302459

Article DOI

10.1534/genetics.119.302459

Usage metrics

    GENETICS

    Categories

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC